• 4 November 2015
    Arsanis Appoints David Mantus as Executive Vice President, Regulatory Affairs, Clinical and Technical Operations

    Arsanis, Inc., a development- stage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, today announced that David Mantus, Ph.D., has joined the company as Executive Vice President, Regulatory Affairs, Clinical and Technical Operations. Dr. Mantus will oversee all facets of Arsanis’ global regulatory affairs, including filings and interactions with the major regulatory authorities around the world as well as clinical operations, manufacturing and quality. Dr. Mantus will report to Rene Russo, PharmD, BCPS, Arsanis’ Chief Development Officer.

    Dr. Mantus joins Arsanis from BIND Therapeutics, where he served as Vice President, Regulatory Affairs and Quality Assurance. Prior to BIND, Dr. Mantus was Vice President of Regulatory Affairs at Cubist Pharmaceuticals.

    “I am delighted that Dave Mantus has chosen to join Arsanis and become a member of our management team,” said Dr. Russo. “Dave is a senior biotechnology leader who brings a strong mix of creativity, global experience, and strategic thinking to Arsanis. We look forward to having him help us realize our vision of translating exciting and novel science into precision therapies that target specific important pathogens.”

    Prior to his time at Cubist, Dr. Mantus held various senior regulatory roles at Sention Inc, Shire Biologics, and PAREXEL. He has also held positions at the Massachusetts Public Health Laboratory and Procter and Gamble Pharmaceuticals, as well as leading a regulatory affairs consulting practice. Dr. Mantus is a co-author of a book on regulatory affairs, "FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics,” that is in its third edition. He has published numerous scientific papers and done presentations around the world. Dr. Mantus received his B.S. in Chemistry at the College of William and Mary, his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington.